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MaOBJECTIVES This study sought to review the literature for risk prediction models in patients with heart failure and to
identify the most consistently reported independent predictors of risk across models.
BACKGROUND Risk assessment provides information about patient prognosis, guides decision making about the type
and intensity of care, and enables better understanding of provider performance.
METHODS MEDLINE and EMBASE were searched from January 1995 to March 2013, followed by hand searches of the
retrieved reference lists. Studies were eligible if they reported at least 1 multivariable model for risk prediction of death,
hospitalization, or both in patients with heart failure and reported model performance. We ranked reported individual risk
predictors by their strength of association with the outcome and assessed the association of model performance with
study characteristics.
RESULTS Sixty-four main models and 50 modiﬁcations from 48 studies met the inclusion criteria. Of the 64 main
models, 43 models predicted death, 10 hospitalization, and 11 death or hospitalization. The discriminatory ability of
the models for prediction of death appeared to be higher than that for prediction of death or hospitalization or prediction
of hospitalization alone (p ¼ 0.0003). A wide variation between studies in clinical settings, population characteristics,
sample size, and variables used for model development was observed, but these features were not signiﬁcantly
associated with the discriminatory performance of the models. A few strong predictors emerged for prediction of death;
the most consistently reported predictors were age, renal function, blood pressure, blood sodium level, left ventricular
ejection fraction, sex, brain natriuretic peptide level, New York Heart Association functional class, diabetes, weight or
body mass index, and exercise capacity.
CONCLUSIONS There are several clinically useful and well-validated death prediction models in patients with
heart failure. Although the studies differed in many respects, the models largely included a few common markers
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441AB BR E V I A T I O N S
AND ACRONYM S
BNP = brain natriuretic peptide
LMIC = low- and middle-
income country
NT-proBNP = N-terminal
pro–B-type brain natriuretic
peptideH eart failure is a common and complexcondition (1–3). Despite recent advancesin diagnosis and management, average
outcomes in patients with heart failure remain poor
and highly variable (4). Risks among subgroups of
patients with heart failure often vary several-fold
and may change substantially over time. Hence,
understanding expected risks and communicating
anticipated future disease trajectories to patients
and their families constitutes important aspects
of patient-physician interactions in heart failure
(5,6). More speciﬁcally, knowledge of future risks
can help patients and clinicians make informed deci-
sions about the initiation and intensity of treatment,
such as device therapy, disease monitoring, or end-
of-life care according to the individual patient’s
need and potential for beneﬁt (7,8). Identiﬁcation of
low-risk patients, on the other hand, could help
reduce patient anxiety and avoid costly interventions
of questionable value (7,8).
However, how to best estimate risk in patients with
heart failure is less clear (6,8,9). A substantial body of
published data has shown that patients’ and clini-
cians’ intuitive judgments about future risk tend to be
inaccurate and highly variable (10–14). This is partly
due to our inability as individual people to simulta-
neously consider and process information about
multiple factors. Furthermore, single predictors of
risk are rarely sufﬁcient for accurate estimation of
risk for common conditions such as heart failure (15).
A solution to this problem is to estimate risk from a
combination of several predictors by using a statisti-
cal multivariable model (15–17).
There has recently been a rapid increase in the
number of statistical models available. How-
ever, without a comprehensive overview, it remains
unclear which, if any, should be applied in clinical
care. Therefore, we reviewed contemporary pub-
lished reports for multivariable statistical models for
prediction of death, hospitalization, or both and
assessed their utility for clinical decision making.
METHODS
We undertook this systematic review according to the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines.
SEARCH STRATEGY FOR IDENTIFICATION OF
RELEVANT STUDIES. We searched MEDLINE and
EMBASE from January 1995 to March 2013 for
articles with terms or subject terms “re-admission” or
“mortality” or “death” or “model” or “predict” and
“heart failure.” The search was limited to human
studies; there was no language restriction. We alsohand searched the reference lists of eligible
studies as well as reviews relating to this
subject for identiﬁcation of additional rele-
vant publications (the detailed search strat-
egy is presented in Online Appendix 1).
REVIEW METHODS AND SELECTION CRITERIA.
Two reviewers independently screened all
titles and abstracts and made decisions re-
garding potential eligibility after full-text review.
Discrepancies in judgment were resolved by a third
reviewer. Studies were eligible if they reported
multivariable models for prediction of risk of death,
hospitalization, or death or hospitalization in people
with heart failure; the derived model included at
least 50 patients who experienced an event during
the observation period, because studies with fewer
cases are unlikely to be sufﬁciently robust for wide-
spread clinical or administrative use; and they
assessed model performance. We excluded studies
that focused on single predictors of risk only, because
these are prone to reporting overly optimistic ﬁnd-
ings due to a number of methodological limitations
(15). We placed no restrictions on study setting,
participant characteristics, or geographic regions.
DATA EXTRACTION. For each included study, the
following information was extracted: study and
patient characteristics, candidate variables consid-
ered for model derivation, ﬁnal model variables and
their strength of association with the outcome,
analytical methods, and model discrimination, cali-
bration, and validation, as reported by the authors.
Discrimination is the ability of a statistical model
to distinguish those subjects who experience the
outcome from those who do not. It is usually reported
using the C statistic. A C statistic of 1 indicates perfect
discrimination, whereas a C statistic of 0.5 indicates
discrimination no better than chance. We deﬁned a C
index of <0.6 as poor, 0.6 to 0.7 as modest, and >0.7
as good. Calibration is deﬁned as how closely
observed estimates of absolute risk agree with ex-
pected estimates from the risk prediction model and
is best assessed graphically. We also recorded internal
or external validation of the model, with the former
being an assessment of model ﬁt and the latter being
an assessment of model generalizability. Internal
validation is determined on the basis of the same data
used to develop the model and is usually assessed via
bootstrapping (18). External validation is assessed by
how well the developed model performs on an inde-
pendent sample (19).
DATA ANALYSIS. We explored whether a priori
deﬁned individual methodological characteristics
were associated with the discrimination of the risk
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442prediction model via Kruskal-Wallis nonparametric
1-way analysis of variance. Models from the same
study that looked at the same outcome but over a
different length of follow-up, or had also reported a
variant of the main model, were excluded from
these analyses. The methodological characteristics
considered were type of outcome, derivation sample
size, source population (i.e., administrative, trial,
patient records), and study design (i.e., retrospective
or prospective). For those studies that reported mul-
tiple models for the same outcome but with different
follow-up times, we investigated whether the time
horizon was associated with the level of discrimina-
tion. To identify the most consistent and strongest
risk predictors across studies, we took the following
approach. First, similar individual predictors were
grouped together (e.g., brain natriuretic peptide [BNP]
and N-terminal pro–B-type brain natriuretic peptide
[NT-pro BNP] into BNP and systolic or diastolic blood
pressure into blood pressure). Then, for each model’s
top 10 predictors, we assigned a weight on the basis
of the predictor’s discriminative ability rank as re-
ported by the authors (usually chi-square, z score, or
p values in the ﬁnal model). For studies that indicated
such ranking, the weight was set from 10 to 1, with the
strongest predictor weighted as 10. For studies in
which the ranking could not be extracted from
the published report, all predictors were equally
weighted as 5. We ﬁnally computed the weighted
score by summing all weights for each predictor
across all studies. Sensitivity analyses were per-
formed by excluding models for which actual ranking
of the predictors was not available, with no impact
on the ﬁnal selection of predictors.
RESULTS
Reviewof 2,678 abstracts and additional hand searches
led to the identiﬁcation of 43 main models for predic-
tion of death, 10 main models for prediction of hospi-
talization, and 11 main models for prediction of death
or hospitalization. Another 50 modiﬁcations or sim-
pliﬁcations of the main models were identiﬁed.
CLINICAL SETTINGS FOR MODEL DEVELOPMENT. The
settings from which patients were identiﬁed varied
widely between the studies. Twenty-ﬁve studies (52%)
included hospitalized patients only (including those
presenting to the emergency department), 10 studies
(21%) included patients presenting to outpatient
clinics, and the remaining 13 studies (27%) either had a
mixed setting (i.e., hospital or outpatient clinics) or
did not specify this further (Online Table 1). Among the
studies that included hospitalized patients, the timing
of data collection for predictors varied from a fewhours after admission to up to the pre-discharge
phase. Consequently, the time horizon of the models
developed ranged from events occurring early during
admission (i.e., over a few days) to more long-term
outcome prediction after discharge (i.e., over a few
years). A large proportion of studies developedmodels
that used data collected in the United States only (23
studies; 48%), and a further 3 studies (6%) included
U.S. sites. We did not ﬁnd any studies that were from
low- and middle-income countries (LMICs), although
some studies were multinational studies that included
data from LMICs (Online Table 1).
HEART FAILURE SUBTYPES. Sixteen studies (33%)
were restricted to patients with heart failure who
had left ventricular systolic dysfunction and 1 study
to patients with preserved systolic function. The
remaining 31 studies (65%) either did not make any
reference to left ventricular systolic function or
included all patients with heart failure. Fifteen of
26 studies that entered left ventricular ejection frac-
tion as a categorical variable into the model retained
ejection fraction as an independent risk predictor
in the ﬁnal model. Overall, ejection fraction was 1 of
the top 5 predictors of risk of death across all studies
evaluated in this review.
CANDIDATE VARIABLES FOR RISK MODELS AND
DATA SOURCES. Selection of candidate variables
for model development and the burden of data
collection were highly variable. For example, 1 study
considered a list of more than 300 diagnoses from
administrative records as predictors of outcome but
did not include any clinical, physiological, or labora-
tory variables (20). Another study included psycho-
logical factors (21), whereas other studies included
novel biomarkers (22). Overall, 14 studies (29%) used
routinely available administrative databases for
model development, of which 4 combined these with
some information from patient records. Nine studies
(19%) relied on patient records only and 26 studies
(54%) prospectively collected information for the
study purposes, of which 19 studies (40%) were on
the basis of clinical trial data (Online Table 1).
MODELS FOR PREDICTION OF RISK OF DEATH. All
43 studies reported the risk of all-cause mortality
(Online Table 2); 1 study (23) also reported on coro-
nary death and another (24) also reported on heart
failure mortality. Models for these speciﬁc causes of
death had a slightly better discriminatory power than
those for all-cause mortality (Online Appendix 2).
Two studies considered repeated measures of risk
over time (in addition to baseline clinical informa-
tion), which appeared to improve their predictive
ability compared with measurements at a single
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443point in time (25,26). Most models incorporated de-
mographics, comorbidities, and physiological and
laboratory measures for risk prediction. Fewer
studies considered social and quality-of-life variables
as potential predictors (Online Table 2).
The median number of ﬁnal predictors for the
most comprehensive model reported in these studies
was 9 (range: 3 to 314). A few variables emerged as
the most consistent and strongest predictors of risk:
age, renal function, blood pressure, sodium level,
ejection fraction, sex, BNP (or NT-pro BNP) level, New
York Heart Association functional class, diabetes,FIGURE 1 Most Consistent and Strongest Predictors of Risk of Deat
Red diamonds depict the entrance of variables into the model as candidat
*Model discrimination is the C-statistic as reported by the authors unles
Appendix 3. BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; N
York Heart Association.weight/body mass index, and exercise capacity. Their
inclusion as a candidate or ﬁnal variable for each of
the 43 models is presented in Figure 1. The discrimi-
native ability of the models was modest to good
(C index range of 0.60 to 0.89) (Online Table 2).
MODELS FOR PREDICTION OF RISK OF HOSPITALIZATION.
Admission to the hospital for any cause was the
outcome in 8 models and heart failure readmis-
sion in the other 2 models. The median number
of ﬁnal predictors reported in these studies was
5 (range: 4 to 29). A few recurrent predictors emerged:h Across Studies
e variables, and blue circles depict their retainment in the ﬁnal model.
s otherwise speciﬁed. The full list of references is presented in Online
T-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New
FIGURE 2 Methodological Characteristics Associated With the
Magnitude of the C Index
Bar charts indicate median with interquartile range.
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444age, sex, renal function, cardiovascular disease, and
heart rate. However, because only 1 study reported
the ranking of the predictive value of variables and
the total number of studies (10) was relatively small,
we could not reliably report the strongest predictors
of risk across studies. The discriminative ability of the
models varied from modest to good (C index range of
0.60 to 0.82) (Online Table 3).
MODELS FOR PREDICTION OF RISK OF DEATH OR
HOSPITALIZATION. The median number of ﬁnal pre-
dictors for the main model reported in these studies
was 10 (range of 5 to 12) (Online Table 4). Among
individual predictors across all models, the following
variables emerged as the most consistent and stron-
gest predictors of risk: renal function, BNP (or NT-
proBNP) level, history of heart failure, age, and blood
pressure. The discriminative ability of the models was
modest to good (C index range of 0.61 to 0.80).
CHARACTERISTICS THAT WERE ASSOCIATED WITH
THE C INDEX. We investigated whether the discrim-
inative ability of the 60 main models that quantiﬁed
the C index was associated with individual method-
ological or other design characteristics of the predic-
tive models. The mean reported C index was strongly
associated with the type of outcome assessed, with
models of risk of death giving higher C indexes than
models of death or readmission, or readmission only
(p for heterogeneity ¼ 0.0003) (Figure 2). There was
no association between the reported C index and thederivation sample size, the source of the data, and the
design of the study (p > 0.21 for all). We also found
that when different time horizons were reported for
the same models, the size of the C index was gener-
ally inversely correlated with the length of follow-up.
However, it was not possible to conduct formal
statistical analyses because many studies did not
report a measure of precision for the C index.
MODEL IMPACT. We did not identify any studies that
formally evaluated the impact of the reported risk
prediction model on the management of patients with
heart failure.
DISCUSSION
We identiﬁed 48 studies that reported 64 main
multivariable models (43 for prediction of risk of
death, 10 for hospitalization, and 11 for death or
hospitalization). The results of our study showed
that despite the multiple differences in clinical
settings, population characteristics, and use of
candidate variables, a few variables emerged as
consistent and strong predictors of risk across
different studies. For prediction of death, these var-
iables comprised age, renal function, blood pressure,
sodium level, ejection fraction, sex, BNP (or NT-
proBNP) level, New York Heart Association func-
tional class, diabetes, weight/body mass index, and
exercise capacity. With the exception of the type of
outcome to be predicted and the duration of follow-
up, none of the other study features investigated
were found to be signiﬁcantly associated with the
ability of the models to discriminate between those
who are likely to experience an event and those who
are not. In particular, there was no evidence to sug-
gest that differences in sample sizes, sources of data
collection (e.g., clinical trial or routine records), or
study designs (prospective vs. retrospective) were
signiﬁcantly associated with reported C indexes.
Although similarities between the studies suggest
that more than 1 risk model is likely to prevail for
wider clinical use, we identiﬁed a few areas in which
differences between the models were signiﬁcant and
could affect clinical decision making. One major
source of heterogeneity in risk discrimination was the
type of outcome to be predicted. On average, models
designed to predict the combined outcome of death
or hospitalization, or of hospitalization only, had a
poorer discriminative ability than those designed to
predict death. This may be because hospitalization is
genuinely more difﬁcult to predict than death
(perhaps because the decision about who to admit to
the hospital is much more dependent on health care
supply [27]) or because there has been less focus on
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445this type of outcome (as evidenced by the smaller
number of published reports). Irrespective of the
underlying causes of such differences, we believe
that efforts are needed to increase the performance of
such models in the future to make them clinically
more useful.
Another important difference between the models
reported was the extent to which they have been
validated. Overall, 36% (23 of 64) of the identiﬁed
models had validated their ﬁndings in an indepen-
dent cohort; among these studies, the authors mainly
reported the discriminatory ability of the externally
validated model (i.e., how the model ranked risk) but
not its calibration (i.e., the differences in observed
and predicted absolute risks in an independent
cohort). Because none of the identiﬁed models in
our study were exclusively derived, recalibrated,
or validated in patients from LMICs, validation
and possible recalibration of existing models in
LMICs will be a welcome addition to the existing
evidence base.
From a clinical perspective, our study suggests
that a number of risk prediction tools are suitable
for use in clinical practice, in particular when the
outcome of interest is death. For example, the
recently reported model by Senni et al. (28) has a
very good discriminatory ability for predicting death
at 1 year (C-statistic of 0.88), has been externally
validated (C-statistic of 0.83), and enables calcula-
tion of risk in a wide range of patients with heart
failure on the basis of easily obtainable risk
markers. Another useful recent model used infor-
mation from 30 prospective studies and approxi-
mately 40,000 patients with heart failure to derive
a simple risk calculator for prediction of death for
up to 3 years (29). The very large size of this study
and the derivation of patients from wide geographic
regions provide a uniquely robust and generalizable
tool to quantify the prognosis of individual pa-
tients. However, these 2 models did not include
BNP because such information was not available
and it may be that inclusion of such biomarkers
could further improve the predictive ability of
these models. For prediction of death early after
presentation to the hospital or emergencydepartment, we found the risk models reported by
Peterson et al. (30) and Lee et al. (31) to be partic-
ularly valuable because of their high discriminative
abilities, independent validation in large cohorts of
patients with heart failure with a wide spectrum of
risk, and the relative simplicity of the risk calcula-
tors from the users’ perspective.
If many useful risk calculators exist, why are they
not routinely used in clinical practice? It could be
argued that many of the models identiﬁed in our study
have only been reported recently and that uptake will
increase over time. However, in other clinical areas in
which models have been available for some time, they
still seem to be underused (32,33). Previous research
on barriers to more widespread use of cardiovascular
prediction tools has shown that many clinicians ﬁnd
risk calculation too time consuming and are not
convinced of the value of information derived from
these models (32). We certainly agree that there is
much room for improving the usability of risk predic-
tion tools, in parallel to further research into
improving model performances. For example, devel-
opment of automated data capturing systems and
better techniques for risk visualization would help to
minimize user burden and could facilitate communi-
cation of risks and uncertainties with patients and
their families.
CONCLUSIONS
We identiﬁed more than 60 multivariable risk pre-
diction models for death, hospitalization, or both in
patients with heart failure. Although these models
differed in many respects, a few common and strong
markers of risk have emerged. Several risk calcu-
lators for prediction of death were identiﬁed that
had sufﬁciently high performance properties for
wider clinical use. However, the same was not the
case for prediction of hospitalization.
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